Dasatinib

Dasatinib is a tyrosine kinase inhibitor used to treat certain types of cancer, specifically chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+). It works by blocking the action of an abnormal protein that signals cancer cells to multiply, thereby inhibiting cancer cell growth. This medication is primarily targeted at patients diagnosed with Ph+ CML or ALL and is taken orally under medical supervision.

Dasatinib was discovered on February 25th 2022 and it currently has a search volume of 27.1K with a growth of +190%.